Video

Emerging CAR T-Cell Therapies in Hematologic Cancers

Author(s):

Xiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.

Xiuli Wang, PhD, research professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, discusses emerging CAR T-cell therapy in hematologic cancers.

Currently available CAR T-cell therapies, although very promising for blood cancers like leukemia and lymphoma, has many challenges, explains Wang. Not all patients respond to CAR T-cell therapy; others might respond but relapse soon after. The reason for these challenges, according to Wang, is that there are not enough CAR T cells in patients.

These newer CAR T cells, which Wang is studying at the City of Hope Comprehensive Cancer Center, allow physicians to expand CAR T cells in patients by using cytomegalovirus (CMV) vaccines. With this new technology, these CAR molecules are introduced into the CMV-specific T cells, allowing the resulting T cells to have 2 specificities; they can recognize tumor and CMV antigens, concludes Wang.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD